

INTERNATIONAL NEUROEPIDEMIOLOGY

P02.001 Development of a Screening Instrument To Estimate the Prevalence of Neurological Morbidity in an African Setting *James H. Bower, Venn Maro, William Howlett, Hugh Reyburn*

P02.002 Neurological Disorders in Rural Africa – Suggestion of a Clinical Algorithm *Erich Schmutzhard, Philipp Mosser, Andrea Winkler*

P02.003 Mild Parkinsonian Signs and Parkinson's Disease in a Population of Nonagenarians *Verónica Domingo-García, Félix Bermejo-Pareja, Elena Carrillo, M^a Teresa Jiménez-López, Julián Benito-León*

CLINICAL ASPECTS OF CEREBROVASCULAR DISEASE

P02.004 Mechanisms, Risk Factors and Imaging Patterns of Ischemic Stroke in Cocaine Users *Alberto Ramos-Sepulveda, Yolanda Reyes-Iglesias, Gustavo Ortiz, Sebastian Koch*

P02.005 Pulmonary Embolism after Hemispheric and Brainstem Ischemic Stroke: Autopsy-Based Study *Michael Piradov, Tatiana Gulevskaia, Elena Gnedovskaya, Julia Ryabinkina, Vladimir Morgunov*

P02.006 Unilateral Pseudotumoral Presentation of Cerebral Venous Thrombosis: Report of Two Cases *Leonardo Halley C. Pimentel, Francisco de Assis A. Gondim, Francisco J. MontAlverne, Gisele R. Oliveira*

P02.007 The Effect of Fasting on Cerebral Venous and Dural Sinus Thrombosis *Mohammad Saadatnia, Mohammad Zare, Farzad Fatehi, Ahura Ahmadi*

P02.008 Do Stroke and TIA Hurt? *Smitha Suravaram, M. Fernanda Bellolio, Sailaja Enduri, Cathrine Claypool, Rahul Kashyap, Robert D. Brown, Latha G. Stead*

P02.009 The Patterns and Plausible Mechanisms of Cerebral Infarction Associated with Coronary Angiography *Bum Joon Kim, Sung-uk Park, Dong-Wha Kang, Jong Kim, Sun Kwon*

P02.010 Clinical Presentation, Treatment, and Outcome of 131 Patients with Cerebral Artery Dissection *Guido J. Falcone, Guillermo Povedano, Paz Zuberbuhler, Sebastian Ameriso*

P02.011 The Dolichosis of the Vertebral Artery and the Medullary Compression by Vertebral Artery, Symptomatic? *Jung Hwa Kim, Sang-Bum Lee, Tae-Beom Ahn, Sung-Sang Yoon, Key-Chung Park, Dae-Il Chang, Kyung Cheon Chung*

P02.012 Ischemic Stroke of the Cortical "Hand Knob" Area: Pathomechanisms and Clinical Course *Nils Peters, Stefanie Muller-Schunk, Tobias Freiling, Marco Duering, Thomas Pfefferkorn, Martin Dichgans*

P02.013 Hemimedullary Syndrome with Ipsilateral Sensorimotor Deficit: A Right Vertebral Dissection Syndrome *Fábio H. G. Porto, Soraya P. Da Silva, Marcos R. G. De Freitas, Gabriel R. De Freitas, Osvaldo J. M. Do Nascimento*

PARKINSON'S DISEASE: CLINICAL

P02.014 New Version of the UPDRS (MDS-UPDRS): Factor Analysis *Christopher G. Goetz, Barbara C. Tilley, Stephanie R. Shaftman, Stanley Fahn, Pablo Martinez-Martin, Werner Poewe, Cristina Sampaio, Matthew Stern, Richard Dodel, Bruno Dubois, Robert Holloway, Joseph Jankovic, Jaime Kulisevsky, Anthony Lang, Andrew Lees, Sue Leurgans, Peter LeWitt, David Nyenhuis, C. Olanow, Olivier Rascol, Anette Schrag, Jeanne Teresi, Jacobus J. van Hilten, Glenn T. Stebbins*

P02.015 What Parkinson's Disease Subtypes Are Associated with Greatest Disability? *Lisa Shulman, Ann Gruber-Baldini, Karen Anderson, Paul Fishman, Stephen Reich, William Weiner*

P02.016 Comparison of Kinesia™ to the Unified Parkinson's Disease Rating Scale: Tremor and Bradykinesia Results *Dustin A. Heldman, David Riley, Brian Maddux, Joseph P. Giuffrida*

P02.017 Evaluating Parkinson's Disease Patients at Home: Utility of Self-Videotaping for Objective Motor, Dyskinesia and ON/OFF Assessments *Vanessa Hinson, Christopher K. Goetz, Sue Leurgans, Lucia M. Blasucci, Jennifer L. Zimmerman, Wenqing Fan, Tiffany Nguyen, Anne Hsu*

P02.018 Parkinson's Disease At-Home Testing Device: Feasibility and Relationship to UPDRS Changes over Six Months *Christopher G. Goetz, Glenn T. Stebbins, Ken Kubota, William C. DeLeeuw, Helen Bronte-Stewart, Rodger Elble, Mark Hallett, John Nutt, Lorraine Ramig, Terence Sanger, Allan D. Wu, Peter H. Kraus, Lucia M. Blasucci, Ejaz A. Shamim, Kapil Sethi, Jennifer Spielman, David Wolff, Andrew S. Grove, Craig B. Taylor*

P02.019 The Angular Rate Measurement Devices for Quantitative Grading the Motor Function in Idiopathic Parkinson's Disease *Do-Young Kwon, Woo-Keun Seo, Moon-Ho Park, Seong-Beom Koh, Kun-Woo Park, Dae-Hie Lee, Ji Won Kim, Kwang-Moon Eum*

P02.020 Stereoacuity and Contrast Sensitivity Do Not Affect Freezing of Gait in Parkinson's Disease *Catherine L. Wielski, Sara Krohn, Cordelia Erickson-Davis, Sotirios A. Parashos*

P02.021 Correlating Upper Extremity and Lower Extremity Motor Impairment in Parkinson Disease to Quality of Life: Which Has the Stronger Influence? *Kim C. Stewart, Hubert H. Fernandez, Michael S. Okun, Charles E. Jacobson IV, Chris J. Hass*

P02.022 WITHDRAWN

P02.023 What Is the Role of Spirituality or Religiosity in Parkinson's Disease? *Sara B. Mitchell, Roger J. Mullins, Karen Anderson, Ann Gruber-Baldini, Terra Hill, Haruko Tanji, Paul Fishman, Stephen Reich, William Weiner, Lisa Shulman*

PARKINSON'S DISEASE: THERAPY

P02.024 Once-Daily Ropinirole 24-Hour Prolonged Release as Adjunct to L-dopa Delays the Onset of Dyskinesia Compared with Carbidopa/Levodopa in Patients with Parkinson's Disease *Kapil Sethi, Ray Watts, Rajesh Pahwa, Nancy Earl*

P02.025 Safety and Tolerability of Tyramine Challenge in Levodopa-Treated Parkinson's Disease (PD) Patients Receiving Rasagiline *Jayne Wilkinson, Suzanne Reichwein, Matthew Stern*

P02.026 Pharmacokinetics and Pharmacodynamics of Novel Levodopa Formulations Combining Immediate- and Extended-Release Components (VADOVA): Comparisons to Sinemet and Sinemet CR in Parkinson's Disease *Peter A. LeWitt, John G. Nutt, Aaron Ellenbogen, Tiffany Nguyen, Ann Hsu*

P02.027 Evaluation of Open-Label Rotigotine Treatment in Advanced Parkinson's Disease *Kelly E. Lyons, Rajesh Pahwa, Babek Boroojerdi*

P02.028 Pardoprunox (SLV308) Improves Motor Symptoms in Patients with Early Stage Parkinson's Disease (PD) – A Double-Blind Placebo-Controlled Multi-Center Study *Juliana Bronzova, Cristina Sampaio, Robert Hauser, Anthony E. Lang, Olivier Rascol, Ad G. M. Theeuwes, Serge V. van de Witte, Guus van Scharrenburg*

P02.029 Effect of Medication Washout on Motor Function in Early Stage Parkinson's Disease *P. Charles, Chandler E. Gill, Peter Konrad, Thomas Davis*

P02.030 LEGATO: Early Rapid Clinical Benefit with Azilect® (Rasagiline Tablets) as Mono- and Adjunct Therapy on Parkinson's Disease (PD) Symptoms – A Multicenter Phase IV Trial *Ronald Wilson, Lauren Seeberger, Dee Silver, Alida Griffith, Jill Conner, Phyllis Salzman*

P02.031 Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Modeling of Istradefylline *Niranjana Rao, William Knebel, Marc Gastonguay, Tatsuo Uchimura, Tim Bergsma, Akihisa Mori*

P02.032 Comparison of Apomorphine and Duodopa for Controlling Motor Fluctuations and Dyskinesias in Advanced Parkinson's Disease *Stefano Tamburin, Emiliana Fincati*

P02.033 Adherence to Rotigotine Treatment in 100 Patients *Cristina Ruiz Huete, Pedro Bermejo, Carmen Terron Cuadrada, Ventura Anciones Rodriguez*

NEUROLOGIC MANIFESTATIONS OF SYSTEMIC DISEASE I

P02.034 Diffusion MRI Changes and the Clinical Course of Steroid Responsive Encephalopathy: A Case Report *Christian Grommes, Catherine Griffin, Katharine A. Downes, Alan Lerner*

P02.035 Neurologic Complications of Lung Transplantation *Sasa A. Zivkovic, Nina Barisic, Kenneth R. McCurry*

P02.036 FDG PET for the Patients with CNS Sarcoidosis and Sarcoidmyositis *Kiyobumi Ota, Taji Tsunemi, Kinya Ishikawa, Takanori Yokota, Hidehiro Mizusawa*

P02.037 Central Nervous System Demyelination in Diabetes *Huey-Jen Lee, Abu Nasar, Ahmad ElGengaih, David Krendel, Nizar Souayah*

P02.038 Diffusion Weighted Magnetic Resonance Imaging in Mitochondrial Encephalopathy *Sanjay Mittal, Jonathan Hosey*

P02.039 Changes in Cerebral Perfusion and Tissue Oxygenation Due to Occlusion of External Carotid Artery *Afshin Divani, Tamara Berezina, Ankur Patel, Reza Pakdamani, Hitaishi Dussa, Adnan Qureshi*

P02.040 West Nile Encephalitis Associated with Reversible Restricted Diffusion of Splenium of Corpus Callosum *Aarti Sarwal, Munish Goyal, Brian Stout, William Roland, Upinder Dhand*

P02.041 Prolonged Cognitive Dysfunction after Recurrent Hypoglycemia *Evanthia Bernitsas, Christopher Horn, Daniel W. Miller, Alan J. Lerner*

P02.042 ALS-Mimic Syndrome in a Patient with High Level of Antiphospholipid Antibody: A Case Report *Farzad Fatehi, Mohammad Saadatnia, Keivan Basiri, Payam Sariaslani*

POSTER SESSION II

TUESDAY, APRIL 15 / 11:30 A.M.–2:30 P.M.

FIRST AUTHORS STAND BY POSTER FROM 12:00 P.M.–1:30 P.M.

P02.043 Acute Delirium Due to Hypercalcemia as a Presenting Manifestation of Pulmonary Sarcoidosis: A Case Report *Asit K. Tripathy, Marco Caccamo, Robert Shields*

P02.044 Diffusion Weighted MR Image Findings in Patients with Hypoglycemia *Jee Hoon Roh, Ji Hyun Kim, Seong-Beom Koh, Jung Youn Choi, YoungSeo Koo*

P02.045 Central Nervous System Involvement in Systemic Lupus Erythematosus: Magnetic Resonance Imaging and Cerebrospinal Fluid Analysis *Fernando Cendes, Carlos Appenzeller, Heloisa Ruocco, Carlos O. Brandão, Leonilda M. B. Santos*

P02.046 Quantitative MRI Analysis and Clinical Significance of Hyperintense White Matter Lesions in SLE Patients *Simone Appenzeller, Andreia V. Faria, Li M. Li, Lilian T. L. Costallat, Fernando Cendes*

P02.047 The Neurocardiac Manifestations in the Left Atrial Myxoma *Saurav Sen, Dipak P. Pandya*

P02.048 Successful Treatment of Cognitive Decline in Sneddon Syndrome Associated with Hepatitis C with Cyclophosphamide *Sheng-Han Kuo, Adriana M. Strutt, Michele York, Joseph Kass*

P02.049 Electrophysiologic Features of Carpal Tunnel Syndrome Associated with Amyloidosis *Mohammad Alsharabati, Stacy Rudnicki*

P02.050 Clinical Study of 35 Patients with Sensory Neuropathy and Impaired Glucose Tolerance *Giseli Quintanilha, Osvaldo J. M. Nascimento, Tania Escada, Marcos De Freitas, Camila Pupe, Joao Daher, Fernando Cardoso, Marco Orsini*

P02.051 Ischemic Stroke as the Initial Presentation of Churg-Strauss Syndrome *Ruxandra M. Costa, David H. Panossian, Petya Gueordjeva*

P02.052 The Differential Diagnosis of Isolated Angiitis of the CNS (IAN) and Bacterial Endocarditis (BE) *Peter Berlit*

P02.053 Psoriatic Arthritis-Associated Painful Small Fiber Neuropathy *Ivan R. F. Da Silva, Osvaldo J. M. Nascimento, Camila Leijoto, Marcos R. G. De Freitas, Giseli Quintanilha, Renata R. Silveira, Glenda Lacerda*

AGING AND DEMENTIA: CLINICAL I

P02.054 Zarit Burden Inventory and Activities of Daily Living in the Behavioral Variant of Frontotemporal Dementia *Claire J. Boutoleau-Bretonniere, Martine Vercelletto, Christelle Volteau, Pierre Renou, Estelle Lamy*

P02.055 Depression and Environmental Factors in Alzheimer Disease in Spain (IDEAL Study). Preliminary Results *Jesús Porta-Etessam, José Luis Tobaruela*

P02.056 Depression Significant in Community-Dwelling Chinese Patients Referred for Subspecialty Dementia Evaluation *Hilary J. Ong, Steven Choy, Marian Tse, Howard Rosen, Joel Kramer, Bruce Miller, Brandy Matthews*

P02.057 Survival Analysis of Patients with Cognitive Impairment and Subtypes of Dementia from a Specialized Dementia Clinic *Ging-Yuek Hsiung, Omar Ayoub, Jonathan Money, Claudia Jacova, Howard Feldman*

P02.058 Anxiety and Apathy Are Associated with Probable REM Sleep Behavior Disorder among Cognitively Normal Elderly Subjects: The Mayo Clinic Study of Aging *Jennifer Molano, Bradley F. Boeve, Rosebud Roberts, Yonas V. Geda, David Knopman, Eric Tangalos, Glenn Smith, Robert Ivnik, Ruth Cha, Vernon Pankratz, Michael Silber, Tanis Ferman, Ronald Petersen*

P02.059 Cognitive Functions in Chronic Inflammatory Demyelinating Polyneuropathy *Jean-Baptiste Chanson, Frederic Blanc, Catherine Kleitz, Yon Andonji Echaniz Laguna, Christine Tranchant, Jerome De Seze*

P02.060 Frontotemporal Lobar Degeneration and Multiple Sclerosis *Paulo R. Shiroma, Maria I. Lapid, Brendan J. Kelley, Daniel A. Drubach, Catarina Giannini, Mark B. Keegan, Bradley F. Boeve, Keith A. Josephs*

P02.061 Progression of MCI to Dementia in Clinic Versus Community Based Cohorts *Sarah Farais, Bruce Reed, Dan Mungas, Charles DeCarli*

P02.062 Twinkle-Twinkle Little Star to Beethoven: A Reversible Immune-Mediated Dementia *Gediminas Gliebus, Andrea Rosso, Carol Lippa*

P02.063 Outcomes of Uncertain Dementia *Catherine M. Roe, Katherine Piwnica-Worms, James Galvin, Martha Storandt, John Morris*

P02.064 The VISN 23 Dementia Demonstration Project *John R. McCarten, Pauline Anderson, Dwight Nelson, Maurice W. Dysken, William Korchik*

P02.065 Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease in Illiterate and Low-Educated Patients *Catherine Belin, Didier Maillet, Elodie Metivet, Herve Le Clesiau, Anne-Marie Ergis, Antoine F. Carpentier, Frederic Dessi*

P02.066 Evaluation of the Usefulness of Self-Reported Memory Decline in a Longitudinal Study of Aging and Cognition *Alicia I. Ford, Bruno Giordani, Judith Heidebrink, Linda Nyquist, Carol Persad, Bin Nan, Chia-Ning Wang, Roger Albin*

P02.067 Basal Ganglia MRI Hyperintensities and Falls in Community-Dwelling Elderly *Nicolaas Bohnen, Martijn M. Muller, Peter Syre, Scott Ziolko, Stephanie Studenski*

P02.068 Detecting Dementia in Ecuador Using the AD8 and CDR Evaluations *Patricio Espinosa, Patricio H. Espinosa, Marta S. Mendiondo, Alberto G. Basantes, Erin Abner, Frederick Schmitt, Roberto M. Velez, Gregory Jicha, German A. Echeverria, Juan P. Espinosa, Fabricio O. Suarez, Thomas Tucker, Richard J. Kryscio, James R. Galvin, Charles Smith*

P02.069 Demographic and Etiologic Characteristics of Young-Onset Dementia *Brendan Kelley, Bradley Boeve, Keith Josephs*

EPILEPSY: CLINICAL CONSIDERATIONS

P02.070 Epilepsy and Motor Vehicle Driving in Argentina *Juan Cardozo Oliver, Tamara Rudy, Alejandra Báez, Mariana Báez, Maria Arrigoni, Patricio Labal, Miguel Copello, Analia Gimeno, Marcela Lopez, Jose Blasco, Estela Lehkuniec, Ignacio Casas-Parera*

P02.071 Sexual Dysfunction in Women with Epilepsy *Lakshminarasimhan Ranganathan, Anitha Ramanathan, A. Murugesan, A. Vengatesan, Srinivasaraman Govindarajan*

P02.072 Cost of Antiepileptic Drug (AED) Usage in Patients with Pseudo-Seizure Disorders *Deepa Nidhiry, Rajiv Padmanabhan, Erik J. Martin, Suparna Krishnaiengar, Kalarickal Oommen*

P02.073 The Head Nodding Syndrome – Clinical Classification and Possible Causes of a New Epilepsy Disorder *Andrea Winkler, Katrin Friedrich, Rebekka König, Michael Meindl, Raimund Helbok, Iris Unterberger, Thaddaeus Gotwald, Jaffer Dharsee, Sandeep Velicheti, Aslam Kidunda, Louise Jilek-Aall, William Matuja, Erich Schmutzhard*

P02.074 Economic Impact of Non-Epileptic Seizures on the Health Care System and the Importance of Their Early Diagnosis and Treatment *Olga Finlayson, Seyed M. Mirsattari, Paul Derry, Jorge Burneo, David Diosy, Warren T. Blume, Richard McLachlan, Bryan Young*

P02.075 Screening for Folate Use in Women of Childbearing Potential with Epilepsy *Kimberly A. Cole, Nabeel A. Herial, Atul K. Ramesh, Lazar J. Greenfield, Jr., Imran I. Ali*

P02.076 Injuries in Pharmacoresistant Epilepsy: A Comparison of Temporal and Extratemporal Epilepsy Patients *David E. Friedman, Frank Gilliam*

P02.077 The Executive Function on the Wisconsin Card Sorting Test in Patients with Mesial Temporal Lobe Epilepsy *Bong-Hui Kang, Sang-ahn Lee, Chul-ho Kim, Joong-koo Kang, Jung-kyo Lee*

P02.078 Practical Ambulatory Screening for Depression in Epilepsy Using Two Screening Instruments *Angelo Wijeyesinghe, Russell Bartt*

P02.079 Interictal Mood Disorder and Quality of Life in Medically Refractory Epilepsy *Steven A. Sandstrom, Vicenta Salanova, Elizabeth Bowman*

P02.080 Public Perception and Attitude towards Epilepsy in North-Eastern Nigeria *Abdullahi Ibrahim, Yakubu Nyandaiti, Sunday Bwala*

P02.081 Risk Factors for Increase in Troponin after Epileptic Seizures in Emergency Room Patients *Kandan Kulandaivel, Sigmund Jenssen*

P02.082 Relations of Serum ACTH COR and Sleep Seizures *Shouwen Zhang, Yuxi Liu*

P02.083 Time to Diagnosis of Pseudo-Seizures by Audio-Video EEG (AVEEG) Monitoring: A Retrospective Analysis *Rajiv Padmanabhan, Erik J. Martin, Suparna Krishnaiengar, Deepa Nidhiry, Kalarickal Oommen*

P02.084 Epilepsy and Arachnoid Cysts in Children *Kohilavani Velayudam, Tobias Loddenkemper, Lori Billinghurst, A. Rothner*

EPILEPSY: THERAPEUTICS

P02.085 Seizure Outcome after Change of Antiepileptic Drug in Seizure-Free and Non-Seizure-Free Patients *Scott Mintzer, Christopher Skidmore, Caitlin Abidin, Maromi Nei, Andro Zangaladze, Michael Sperling*

P02.086 In-Hospital Complications of Epilepsy Surgery: A Six-Year Nationwide Experience *Araya Puwanant, Amer Alsheklee, Syed U. Tanvir, Mohamad Koubeissi*

P02.087 Effect of Long-term Antiepileptic Drug Therapy on Lipid Profile *Lakshminarasimhan Ranganathan, A. Kogulavadanan, Aparna Vijayasekaran, Navaneeth Chandru Kumar, A. Murugesan, Vengatesan Appasamy*

P02.088 Lamotrigine-Valproic Acid Combination Therapy for Medically Refractory Epilepsy *Jeremy J. Moeller, Susan R. Rahey, R. Mark Sadler*

P02.089 Verapamil in Refractory Status Epilepticus – A Case Report *Devanshi Gupta*

P02.090 Pregabalin Add-On Treatment Using a Flexible, Optimized Dose Schedule in Asian Subjects with Partial Seizures *Byung-In Lee, Teresa Leon, Jae-Won Lee*

P02.091 Intravenous Levetiracetam: A New Treatment Alternative for Status Epilepticus *Gabriel Moddel, Sabine Buntgen, Clemens Dobis, Rainer Dziewas, Wolf-Rudiger Schabitz, Stefan Evers, Svenja Happe*

P02.092 Once-Daily Extended-Release Levetiracetam as Add-On Therapy in Patients with Refractory Partial-Onset Seizures: Double Blind, Placebo-Controlled Trial *Jukka Peltola, Christo Coetzee, Fiacro Jiménez, Tetyana Litovchenko, R. Sridharan, Leonid Zaslavskiy, Deanne Sykes, Sarah Lu*

P02.093 Variables Associated with Weight Gain during Treatment with Pregabalin for Epilepsy *Marlis Frey, Andres M. Kanner, Jill M. Gattone, Glenn Stebbins*

P02.094 Exploratory Assessment of Behavioral and Emotional Function in Children and Adolescents with Partial-Onset Seizures Treated with Adjunctive Levetiracetam in a Randomized Placebo-Controlled Trial *Christine De la Loge, Scott Hunter, Jimmy Schiemann, Haichen Yang*

P02.095 A Head to Head Comparison of Pregabalin and Lamotrigine, Including a Third Placebo Arm, as Adjunctive Therapy in Patients with Refractory Partial Onset Seizures *Michel Baulac, Teresa Leon, Ed Whalen, Jeannette Barrett*

P02.096 Worsening of Generalized Epilepsy with the Anti-Epileptic Drug Oxcarbazepine *Peter Widdess-Walsh, Aviva Bojko, Eric Geller, Rina Goldberg, Mangala Nadkarni, Orrin Devinsky*

P02.097 Lacosamide: Efficacy and Safety as Oral Adjunctive Treatment for Partial-Onset Seizures *Steve Chung, Michael Sperling, Victor Biton, Gregory Krauss, Margaret Beaman, David Hebert*

P02.098 Co-Morbidities and Co-Medication Use in Epilepsy Patients Receiving Antiepileptic Treatment in a Managed Care Setting *Jamie B. Forlenza, Jason Yeaw, Yanmei Liu, Marcia Rupnow*

P02.099 In-Hospital Mortality and Complications of Hemispherectomy: Analysis of a Nationwide Sample *James Jordan, Amer Alshekhelee, Tanvir Syed, Mohamad Koubeissi*

P02.100 "What Does a Seizure Sound Like?" The Diagnostic Utility of the Epileptic Cry *Hoda Elzawahry, Shirely Chen, Selim Benbadis*

P02.101 Intravenous Levetiracetam in Children: A Prospective, Safety Study *Yu-tze Ng, Emily M. Khoury*

P02.102 Effects of Once-Daily Lamotrigine Extended-Release as Adjunctive Therapy in Patients with Primary Generalized Tonic-Clonic Seizures *Victor Biton, Alain Vuong, Anne Hammer, Bryan E. Adams, Susan Kerls, John Messenheimer*

P02.103 One Year of Clinical Experience with Intravenous Levetiracetam in an Academic Medical Center *Jill W. Miller-Horn, Tejwant Bindra, Mary Andriola*

P02.104 Evaluation of Pregabalin for Maintaining Seizure Freedom in Patients with Partial-Onset Epilepsy: Pooled Analysis of Six Long-Term, Open-Label Clinical Trials *Teresa Leon, Birol Emir, Reina Benabou*

P02.105 New Onset Seizure in Elderly: Clinical, Radiological and EEG Characteristics *Mubashira Hashmi, Shaista A. Siddiqui, Mughees Sheerani, Farukh S. Khan, Khurram A. Siddiqui*

P02.106 Efficacy of Pregabalin Treatment in Patients with Partial-Onset Epilepsy: Pooled Analysis of Six Long-Term, Open-Label Clinical Trials *Carl Bazil, Teresa Leon, Birol Emir, Reina Benabou*

P02.107 Effect of Comorbid Somnolence and Depression on Quality of Life in Persons with Epilepsy *Atul K. Ramesh, Nabeel Herial, Kimberly Wilson, Kimberly A. Cole, Andrea Korsnack, Imran I. Ali, L. John Greenfield, Jr.*

P02.108 Vitamin D and Calcium Supplementation and Occurrence of Bone Fractures in Patients with Epilepsy *Patricio Espinosa, Erin L. Abner, Marta S. Mendiondo*

P02.109 Long-Term Follow-Up Results with Vagus Nerve Stimulation in Children with Drug Resistant Epilepsy *Shakti K. Agrawal, Chris D. Rittey*

P02.110 Phenytoin Worsens Balance in Older People with Epilepsy *Terry D. Fife, Joseph Sirven, Joseph Drazkowski, Stacie R. Segebart, Katherine H. Noe, Qing Wu*

P02.111 Safety and Tolerability of Add-On IV Levetiracetam in Status Epilepticus: A Feasibility Study *Marc D. Van Huizen, Joris W. F. Uges, J. Engelsman, Karin Boutrus, Erik B. Wilms, Daan J. Touw, Els A. Peeters, Charles J. Veitch*

P02.112 Pharmacological Profile of Perampanel: A Novel, Non-Competitive Selective AMPA Receptor Antagonist *Naoki Tokuhara, Shinji Hatakeyama, Hiroyuki Amino, Takahisa Hanada, Yukio Nishizawa*

P02.113 Anticonvulsant Activity of Perampanel, a Selective AMPA Receptor Antagonist, in Rodent Models of Epileptic Seizure *Yutaka Hashizume, Takahisa Hanada, Aichi Ogasawara, Masataka Ueno, Yukio Nishizawa*

P02.114 False Positive Phencyclidine (PCP) Results in Patients Taking Lamotrigine *Ravi Patel, Sushma Manda, Robert Beach*

NEUROMUSCULAR DISEASE: THERAPEUTICS

P02.115 Double-Blind Randomized Controlled Trial of SNT-MC17/ Idebenone in Duchenne Muscular Dystrophy *Gunnar M. Buysse, Luc Mertens, Marleen van den Hauwe, Daisy Thijs, Imelda J. M. De Groot, Ulrike Schara, Bertien Ceulemans, Thomas Meier, Nathalie Goemans*

P02.116 How Frequently Are Corticosteroids Used in Boys with Dystrophinopathy in the USA: Data from the MDSTARnet *Emma Gafaloni, Shree Pandya, Dennis J. Matthews, Katherine James, Katherine D. Mathews, Tim M. Miller, MDSTARnet*

P02.117 Immediate Release Oral Pentoxifylline Is Poorly Tolerated in Duchenne Muscular Dystrophy Boys *Carolina Tesi-Rocha, Nancy Kuntz, Paula Clemens, Susan Iannaccone, Alan Pestronk, Angela Zimmerman, Erik Henricson, Adrienne Aarieta, Lei Nei, Bruce Markle, Anne Connolly, Diana Escolar*

P02.118 Pentoxifylline Treatment Fails To Rescue Muscle Strength and Function Deterioration in Prednisone-Treated Duchenne Muscular Dystrophy *Diana Escolar, Ksenija Gorni, Ana Tesi-Rocha, Jean Mah, Yoram Nevo, Andrew Kornberg, Hannah Kolski, Tulio Bertorini, Anne Connolly, Nancy Kuntz, Paula Clemens, Angela Zimmerman, Lauren Morgenroth, Jill Mayhew, Julaine Florence, Lei Nei, Fenming Hu, Tina Duong, Erik Henricson, Robert Leshner, Alberto Dubrovsky*

P02.119 Defining Treatment Outcomes for the Cardiomyopathy of Dystrophin-Deficiency *Laurence Viollet, Subha Raman, Stephen Cook, Susan Gailey, John Kissel, Ziad Haddad, Faisal Raja, Majed J. Dasouki, Mazen Dimachkie, Kenneth Goertz, Richard Barohn, Jerry Mendell, Hugh Allen*

P02.120 SNT-MC17/Idebenone for the Treatment of Patients with Friedreich's Ataxia: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Efficacy and Safety *David Lynch, Susan Perlman, Pierre Vankan, Thomas Meier*

P02.121 Effects of One Year Enzyme Replacement Therapy in Severe Form of Late Onset Pompe Disease. Severe Late Onset Treatment Study (French SLOTS) *David Orlikowski, Pascal Laforet, Nadine Pellegrini, Helene Prigent, Aurélien Monnet, Pierre Carlier, Robert Carlier, Bruno Eymard, Frederic Lofaso, Djilalli Annane*

P02.122 Molecular Pathology and Response to Enzyme Replacement Therapy in Late-Onset Phenotypes of Acid Maltase Deficiency (AMD) *Corrado Angelini, Andrea Semplicini, Annachiara Nascimbeni, Marina Fanin*

P02.123 Aggressive Immunotherapy Is Successful in Treating Sporadic Late Onset NemaLine Myopathy (SLONM) *Jan Novy, Murielle Dunand, Thomas Pabst, Anne Rosselet, Olivier Spertini, Johannes Alexander Lohrinus, Thierry Kuntzer*

P02.124 Safety of Intravenous Immune Globulin (IVIg) in the Home Setting in Patients with Autoimmune Neuromuscular Disorders *Michael T. Rigas, Zahid Cheema*

NEUROMUSCULAR JUNCTION AND MUSCLE DISEASE: DIAGNOSIS AND TREATMENT

P02.125 Long-Term Immunosuppressive Treatment for Myasthenia Gravis: An 11-Year Experience *Minas Tzougounissakis, Georgios Amoiridis, Andreas Plaitakis*

P02.126 Clinical and Laboratory Differences among Three Types of Generalized Myasthenia Gravis *Angela Young, Gwen Claussen, Marla Morgan, Liang Lu, Yuki Hatanaka, Shoji Hemmi, Shin J. Oh*

P02.127 Thymectomy in Juvenile Autoimmune Myasthenia Gravis *Claudio G. Mazia, Valeria L. Salutto, Hugo Arroyo, Alejandra Soraru*

P02.128 A New Immune Reconstitution Inflammatory Syndrome (IRIS): Myasthenia Gravis (MG) with Antibodies Against MuSK in an HIV-Infected Patient *Antonio Carota, Jan Novy, Christian Chuard, Renaud Du Pasquier, Thierry Kuntzer*

P02.129 Neuromuscular Junction Dysfunction in Diabetic Neuropathy *Carmen C. Garcia, Natalya Krivitskaya, Joseph J. McArdle, Vanessa H. Routh, Joseph G. Potian, Nizar Souayah*

P02.130 Paraneoplastic Stiff Person Syndrome (SPS) in Patients with Anti-GAD Antibodies: Report of 2 Cases with SPS-Specific Antigens in Their Tumors *Goran Rakocovic, Cristina Semino-Mora, Marinos Dalakas*

POSTER SESSION II

TUESDAY, APRIL 15 / 11:30 A.M.–2:30 P.M.

FIRST AUTHORS STAND BY POSTER FROM 12:00 P.M.–1:30 P.M.

P02.131 A Necrotizing Myopathy Associated with Statin Use Is Responsive to Immunomodulatory Agents *Hans Katzberg, Robert G. Miller, Phyllis Grable, Jarasrhi Srinivasan, Steven A. Greenberg, Jonathan Katz, Anthony Amato*

P02.132 Paraspinal Muscle Biopsies: A Clinical and Electromyographic Study *Jayashri Srinivasan, Kara Chisholm, Stephanie Scala, H. Jones*

P02.133 Sleep-Disordered Breathing in Oculopharyngeal Muscular Dystrophy: A Clinical and Polysomnography Study *Marcel Hungs, Karen Cheng, Luis Chui*

MULTIPLE SCLEROSIS AND RELATED DISEASES: THERAPEUTICS

P02.134 The Efficacy of BG00012 in Patients with Relapsing-Remitting Multiple Sclerosis: Subgroup Analyses from the Phase 2b Study *Ludwig Kappos, David Miller, David MacManus, Ralf Gold, Eva Havrdova, Volker Limmroth, Chris Polman, Klaus Schmierer, Tarek Yousry, Minhua Yang, Mefkure Eraksoy, Eva Meluzinova, Ivan Rektor, Katherine Dawson, Gilmore N. O'Neill*

P02.135 A Short-Term MRI Study Comparing High-Dose Oral Versus Intravenous Methylprednisolone in MS Relapses *Vittorio Martinelli, Annalisa Pulizzi, Pietro Annovazzi, Maria A. Rocca, Mariemma Rodegher, Federica Esposito, Filippo Martinelli Boneschi, Roberta Scotti, Andrea Falini, Giancarlo Comi, Massimo Filippi*

P02.136 Site Performance in an Investigator-Run Multiple Sclerosis Clinical Trial *Jeffrey Cohen, Peter Imrey, Peter Calabresi, Swati Chakraborty, Keith Edwards, Thorsten Eickenhorst, Warren Felton, Elizabeth Fisher, Robert Fox, Andrew Goodman, Claire Hara-Cleaver, George Hutton, Brian Mandell, Thomas Scott, Hao Zhang*

P02.137 Autologous Attenuated T Cell Vaccine (Tovaxin®) Dose Escalation in Multiple Sclerosis Relapse-Remitting and Secondary Progressive Patients Nonresponsive to Approved Immunomodulatory Therapies *Brian Loftus, Brian Newsom, Mitzi Montgomery, Von Gynz-Rekowski Kathrin, Mary Riser, Shannon Inman, Pablo Garces, Donna Rill, Jim Williams*

P02.138 Is Brain Atrophy Progression in RR-MS Slowed by the Association of Atorvastatin and Interferon Beta-1a? Preliminary Results from an Open-Label, Randomized, Clinical Study *Mario Quarantelli, Giuseppe Orefice, Anna Prinster, Roberta Lanzillo, Petronilla Salvatore, Carmine Mollica, Elena Salvatore, Arturo Brunetti, Bruno Alfano, Vincenzo Brescia Morra*

P02.139 Interferon Beta-1a and Atorvastatin Combination Therapy: 12-Month Results from an Open-Label, Randomized, Clinical Study *Giuseppe Orefice, Mario Quarantelli, Petronilla Salvatore, Arturo Brunetti, Roberta Lanzillo, Anna Prinster, Giovanni Vacca, Carmine Mollica, Vincenzo Bonavita, Vincenzo Brescia Morra*

P02.140 Relation between MRI and Therapeutic Plasma Exchange (PLEX) Response in Patients with Fulminant CNS Inflammatory Demyelinating Disorders (IDD) *Setty Magana, Mark Keegan, Brian Weinshenker, Bradley J. Erickson, Jay N. Mandrekar, Stephen D. Weigand, Kristine Thomsen, Linda Linbo, Claudia Lucchinetti*

P02.141 Effect of Infertility Treatment on Multiple Sclerosis: Report of 4 Cases *Girish Hiremath, Deanna Cettomai, Mathew Pulicken, John Ratchford, Peter Calabresi*

P02.142 The Interferon Beta-1b 16-Year Long-Term Follow-Up Study: Predictive Clinical and Magnetic Resonance Imaging Markers *Douglas Goodin, David Li, Anthony Traboulsee, Anthony Reder, Jason Jones, Karola Beckmann, Andreas Konieczny, George Ebers*

P02.143 The Effect of Parenteral Cladribine on Relapses and Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis: Results of a 2-Year, Double-Blind, Placebo-Controlled, Crossover Study *Zbigniew Stelmasiak, Janusz Solski, Jacek Nowicki, Beata Jakubowska, Miroslaw Ryba, Pawel Grieb*

P02.144 Safety and Tolerability of the First Single-Use, Fully Integrated Autoinjector for IM Interferon Beta-1a *J. Phillips, Bianca Weinstock-Guttman, Warren Felton, Jeffrey English, Howard Rossman, Keith Edwards, William Honeycutt, William Sheremata*

P02.145 High-Dose Atorvastatin Alone or in Combination with Interferon-beta (IFN-beta) in the Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) *Paul Friedemann, Orhan Aktas, Sonia Waiczies, Jens Würfel, Judith Bellmann-Strobl, Jan-Markus Dörr, Helmar Waiczies, Mareile Haertle, Klaus-Dieter Wernecke, Hans-Dieter Volk, Frauke Zipp*

P02.146 Short-Term Effects of Medicinal Cannabis on Spasticity in Multiple Sclerosis *Jody Corey-Bloom, Tanya J. Wolfson, Gamst C. Anthony, Heather Bentley, Ben Gouaux*

P02.147 Effects of Subcutaneous Interferon Beta on Disease Parameters and Cognition in Patients with Early Relapsing-Remitting Multiple Sclerosis: Longitudinal Clinical and Cognitive Results from the COGIMUS (COgnition Impairment in MULTiple Sclerosis) Study *Francesco Patti, Maria Pia Amato, Maria Rosalia Tola, Maria Trojano, Paolo Ferrazza, Anrea Fausto Lijoi, Stefano Bastianello*

P02.148 Neutralizing Antibodies Did Not Affect Efficacy of Interferon beta-1b: Further Analysis of the Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment Study (BENEFIT) *Mark S. Freedman, Gilles Edan, Hans-Peter Hartung, Ludwig Kappos, David H. Miller, Xavier Montalbán, Chris H. Polman, Lars Bauer, Vivian Lanius, Christoph Pohl, Rupert Sandbrink*

P02.149 A Pilot Trial of Low Dose Naltrexone in Primary Progressive Multiple Sclerosis *Maira Gironi, Filippo Martinelli, Paola Sacerdote, Claudio Solaro, Rosella Cavarretta, Mauro Zaffaroni, Lucia Moiola, Marta Radaelli, Valentina Pilato, Sebastiano Bucello, Vittorio Martinelli, Marco Cursi, Raffaello Nemni, Giancarlo Comi, Gianvito Martino*

P02.150 The CARE-MSSM II Trial (Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis): Design of a Phase 3, Open-Label, Rater and Dose-Blinded Study of Alemtuzumab in Patients with MS Who Have Relapsed on Therapy *Edward Fox, CARE-MS Steering Committee and CARE-MS Design Team*

P02.151 A Single Center, Randomized, Placebo-Controlled, Double-Crossover Study of the Effects of Low Dose Naltrexone on Multiple Sclerosis Quality of Life *Bruce Cree, Michael Ross, Ivo Violich, Brendan Berry, Azadeh Beheshtian, Elena Korniyeyeva, Douglas Goodin*

P02.152 The Real Life Impact of Early Versus Delayed Treatment of Interferon beta on Long-Term Disability Progression in Relapsing-Remitting Multiple Sclerosis *Maria Trojano, Maria Pia Amato, Carlo Avolio, Roberto Bergamaschi, Paola Cavalla, Luca Durelli, Aurora Fuiani, Angelo Ghezzi, Alessandra Lugaresi, Giacomo Lus, Enrico Millefiorini, Damiano Paolicelli, Francesco Patti, Fabio Pellegrini, Carlo Pozzilli, Paolo Rossi, Giuseppe Solemi, Marica Vianello, Paolo Livrea, Giancarlo Comi*

P02.153 Treatment Effect of IFN-beta Is Restored after Disappearance of Neutralizing Antibodies *Per Soelberg Sorensen, Nils Koch-Henriksen, Esben Meulengracht Flachs, Klaus Bendtzen*

P02.154 Detection of JC/BK Virus in Patients with Multiple Sclerosis Treated with Natalizumab *Lauren M. Puccio, Jacqueline Dinzey, Christina A. Poopatana, Kathleen V. Barrett, Saud A. Sadiq*

P02.155 The Changing Face of Multiple Sclerosis Clinical Trial Populations: Implications for Ongoing and Future Clinical Studies *Bernard Uitdehaag, Fred Barkhof, Peter Chang, Patricia K. Coyle, Douglas Jeffery, Daniel Mikol, Steven Schwid, Bettina Stubinski*

P02.156 Natalizumab Increases the Proportion of Patients Free of Clinical or MRI Disease Activity in Relapsing Multiple Sclerosis *Steven Galetta, Peter Calabresi, Christian Confavreux, Gavin Giovannoni, Eva Havrdova, Michael Hutchinson, Ludwig Kappos, Fred Lublin, David Miller, Paul W. O'Connor, J. Phillips, Chris Polman, Ernst-Wilhelm Radue, Richard Rudick, William Stuart, Andrzej Wajgt, Bianca Weinstock-Guttman, Daniel Wynn, Amy Pace, Robert Hyde, Richard Kim, Michael Panzara*

P02.157 Efficacy and Safety of Natalizumab as Escalation Therapy in Relapsing-Remitting Multiple Sclerosis *Norman Putzki, Kollia Kiriaki, Zaza Katsarava, Sophia Woods, Ezinne Igwe, H. Diener*

P02.158 Mycophenolate Mofetil in the Treatment of Multiple Sclerosis *Siddharama Pawate, Lily Wang, Subramaniam Sriram, Harold Moses*

P02.159 Repetitive Transcranial Magnetic Stimulation Can Improve Walking in Multiple Sclerosis Patients with Spastic Paraparesis *Spyros N. Desteos, Gregory N. Panagopoulos, Dimitra Georgonikou, Sofia Katsarou, Labros Doumas, Elissaios Karageorgiou, Clementine E. Karageorgiou*

P02.160 The Efficacy of Cladribine in Relapsing-Remitting Multiple Sclerosis: Clinical Data from a Randomized, Double-Blind, Placebo-Controlled, 18-Month, Phase II Trial *Jack Sipe, Jason Gardner, Ernest Beutler*

P02.161 Impression of Clinical Worsening Fails To Predict Interferon-beta Neutralizing Antibody Status *Jan Hillert, Uros Rot, Ajith Sominanda, Anna Fogdell-Hahn*

P02.162 Autologous Hematopoietic Stem Cell Transplantation Following High-Dose Immunosuppressive Therapy in Multiple Sclerosis: Six-Year Results *James D. Bowen, George H. Kraft, Annette Wundes, QingYan Guan, Kenneth R. Maravilla, Leona A. Holmberg, Joseph Zunt, Theodore A. Gooley, Bernadette A. McLaughlin, Gretchen R. Henstorf, Richard A. Nash*

P02.163 Does an Innovative Automated Recruitment Process Generate an Unbiased Study Sample from a Pool of Eligible Patients? *Deborah M. Miller, Robert Fox, Ashish Atreja, Shirley Moore, Jar-Chi Lee, Alex Fu, Welf Saube, Swati Chakraborty, Maria Stadler, Richard Rudick*

P02.164 Glatiramer Acetate after Induction with Mitoxantrone in Secondary Progressive Multiple Sclerosis *Adriana Carrá, Patricia Onaha, Mario J. Halfon, Vladimiro Sinay*

P02.165 How To Prevent Conversion from Clinically Isolated Syndromes to Clinically Defined Multiple Sclerosis? A Cochrane Meta-Analysis of Published Trials *Marinella Clerico, Fabrizio Faggiano, Jacqueline Palace, Maria Tintore-Subirana, George P. Rice, Luca Durelli*

P02.166 Short and Long-Term Clinical Efficacy and Safety Outcomes for Multiple Sclerosis (MS) Patients Receiving Mitoxantrone Therapy in Western New York Outpatient Clinical Care Settings *Diane Cookfair, David Hojknacki, Robert Zivadinov, Peter Kinkel, Jyotsna Rajeswary, Fredrick Munschauer, Bianca Weinstock-Guttman*

P02.167 High Doses Immunosuppression Antecedent by Rescue of Hematopoietic Stem Cells and Followed by Its Intravenous Infusion *Amilton A. Barreira, Doralina G. B. Souza, Ana-Beatriz P. L. Stracieri, Maria-Carolina B. Oliveira, Danielle F. Godoi, Daniela A. Moraes, Marina A. Coutinho, Wilson Marques, Jr., Julio C. Voltarelli*

P02.168 The Effect of Levetiracetam on Cerebellar Intention Tremor in Patients with Multiple Sclerosis *Karen M. Fisher, Mark R. Baker, Philip P. Nichols, Stuart N. Baker*

P02.169 Diagnosis Criteria and MRI at Baseline in CombiRx – A Preliminary Analysis *Stacey S. Cofield, Jerry Wolinsky, Ponnada Narayana, Flavia Nelson, Robin Conwit, Fred Lublin, Gary R. Cutter*

P02.170 Low-Dose Mitoxantrone as Add-On Therapy in Multiple Sclerosis Unresponsive to Interferon-beta *Davide Maimone, Marco Bianca, Giuseppe Zappalá, Valentina Virzi, Francesca Matta, Mario Leonardo*

P02.171 The CARE-MSSM I Trial (Comparison of Alemtuzumab and Rebif[®] Efficacy in Multiple Sclerosis): Design of a Phase 3, Open-Label, Rater-Blinded Study of Alemtuzumab in Treatment-Naïve Patients with Relapsing MS *Eva Havrdova, CARE-MS Steering Committee and the CARE-MS Design Team*

P02.172 Successful Treatment of Pyoderma Gangrenosum with a TNF α Blocker in a Subject with Multiple Sclerosis *Edward Kim, Eric Edgar, Scott Isenbath, Andrew Blauvelt, Dennis Bourdette, Ruth Whitham*

P02.173 Improvement in Multiple Sclerosis-Related Demyelinating Peripheral Neuropathy Following Aggressive Mitoxantrone Therapy *Brent Goodman, Jonathan Carter, Dean Wingerchuk*

P02.174 Medical Reasons for Dose Adjustment and/or Discontinuation of Mitoxantrone in Clinical Practice *Annette Wundes, George Kraft, James Bowen, Ted Gooley, Richard Nash*

P02.175 A Randomized, Open-Label, Parallel-Group, Multicenter Study To Determine the Safety and Efficacy of Mycophenolate Mofetil (Cellcept[®]) in Mono- and Combination-Therapy with Interferon beta-1a (Avonex[®]), in Patients with Relapsing-Remitting Multiple Sclerosis *Robert Zivadinov, Gary Cutter, Howard Rossman, Bianca Weinstock-Guttman, Jacqueline Durfee, Jennifer Cox, Gina Remington, Sonda Perez, Michael G. Dwyer, Michael Racke, Anjali Shah, Elliot Frohman*

P02.176 Glatiramer Acetate (GA) Is Effective in Neutralizing Antibodies to IFN β Positive (NAb+ve) Multiple Sclerosis (MS) Patients *Marco Capobianco, Simona Malucchi, Francesca Sperli, Alessia Di Sapio, Alessandra Oggero, Paola Valentino, Letizia Granieri, Fabiana Marnetto, Marzia Caldano, Francesca Gilli, Arianna Sala, Antonio Bertolotto*

P02.177 Effects of Mitoxantrone Treatment on Cognitive and Physical Disability in Patients with Multiple Sclerosis *Serkan Ozakbas, Egemen Idiman, Derya Kaya, Turan Poyraz, Esra Coskuner Poyraz*

P02.178 Multiple Sclerosis Related Fatigue Improves after Treatment Initiation with Natalizumab *Sophia Woods, Ezinne Igwe, Zaza Katsarava, Norman Putzki*

P02.179 Phase II Clinical Trial (Halt MS: Immune Tolerance Network) of High Dose Immunosuppressive Therapy (HDIT) and Autologous Hematopoietic Stem Cell Transplantation (AHCT) for Active Relapsing-Remitting (RR) Multiple Sclerosis (MS): Early Results *George Kraft, James Bowen, Harry Openshaw, Stephen J. Forman, Elliot Frohman, Linda M. Griffith, George Hutton, Paolo A. Muraro, Uday Papat, Michael Racke, Peter Sayre, Olaf Stuve, Annette Wundes, Richard A. Nash*

P02.180 A Combined Analysis of Data from Four Randomized, Double-Blind, Placebo-Controlled Trials of Parenteral Cladribine and One Open-Label Pilot Study To Assess the Safety and Tolerability Profile of Repeated Periods of Cladribine Treatment in Patients with Progressive or Relapsing Multiple Sclerosis *Stuart Cook*

AGING AND DEMENTIA: TREATMENT

P02.181 Effects of Postmenopausal Hormone Therapy on Regional Brain Volumes in Older Women: The Women's Health Initiative Magnetic Resonance Imaging Study (WHIMS-MRI) *Susan M. Resnick, Mark A. Espeland, Sarah A. Jaramillo, Calvin Hirsch, Marcia L. Stefanick, Anne M. Murray, Judith Ockene, Christos Davatzikos*

P02.182 Memantine Augments the Effects of Cholinesterase Inhibition in the Treatment of Alzheimer's Disease *Oscar L. Lopez, James T. Becker, Abdus S. Wahed, Judith Saxton, Robert A. Sweet, David Wolk, William Klunk, Steven T. DeKosky*

P02.183 High Antioxidant Micronutrient Status Increases Cognitive Function in Healthy Subjects *Maria Cristina Polidori, Domenico Pratico, Wilhelm Stahl, Patrizia Mecocci, Gereon Nelles*

P02.184 Discontinuation of Memantine Therapy in Nursing Home Residents with Alzheimer's Disease Is Associated with Increased Utilization of Psychotropic Medications and Decreased Body Weight *Howard Fillit, Robert K. Hofbauer, Juliana Setyawan, Malca Resnick, Stavros Tourkodimitris, Moshe Fridman, Haim Erder, Constantine Lyketsos*

P02.185 Levetiracetam: Seizure Management for Elderly Patients with Cognitive Impairment *Carol Lipka, Gonzalo Revuelta, Gediminas Glebus, David Irwin, Marjorie Hepler, Andrea Rosso*

P02.186 LX6171: A Novel Potential Treatment for Cognitive Disorders *Philip Brown, Ted Wagner, Kenny S. Frazier, Daniel W. Walke, Alan G. E. Wilson, William E. Heydorn, Thomas H. Lanthorn*

P02.187 2002-2007 Blueberry Health Study Report: Individual Data Sets Are Now Reaching the 95% Confidence Level *Rolf J. Martin, Barrie S. Sachs, Roseanne Schnoll, Kathy Hull, Howard A. Raphaelson*

P02.188 Measuring Progression of Disease in Frontotemporal Dementia: Therapeutic Trial Implications *Christopher Kipps, Peter J. Nestor, Kate Dawson, Joanna Mitchell, John R. Hodges*

P02.189 Dimebon Improves Patient Function and Decreases Caregiver Assistance Time in Alzheimer's Disease: One-Year Clinical Trial Results *Rachelle S. Doody, Svetlana Gavrilova, Paul Aisen, Mohammad Hirmand, Mary Sano*

P02.190 Effects of Postmenopausal Hormone Therapy on Volumetric Sub-Clinical Cerebrovascular Disease: The Women's Health Initiative Memory Study – Magnetic Resonance Imaging Study (WHIMS-MRI) *Laura H. Coker, Patricia E. Hogan, Nick R. Bryan, Lewis Kuller, Karen L. Margolis, Kerstin Bettermann, Robert B. Wallace, Zhiqiang Lao, Ruth Freeman, Marcia L. Stefanick, Sally A. Shumaker*

P02.191 Mathematical Comparison of a Randomized-Withdrawal Clinical Trial Design and a Parallel-Group Design To Demonstrate Disease Modification in Alzheimer's Disease (AD) *Suzanne Hendrix, Alexander Gutin*

P02.192 The Effect of Cholinesterase Inhibitors on the Levels and Activities of Cholinesterases in the Cerebrospinal Fluid of Alzheimer's Disease Patients *Martin Farlow, Taher Darreh-Shori, Elaine Peskind, Gustavo Alva, Gina Eagle, Agneta Nordberg*

P02.193 Effects of Memantine on Language and Functional Communication in Patients with Moderate to Severe Alzheimer's Disease Receiving Stable Doses of Donepezil *Michael Tocco, Judith Saxton, Pierre N. Tariot, Robert K. Hofbauer, Malca Resnick, Stephen M. Graham*

P02.194 Chronic Administration of Melatonin in Drinking Water Decreases Synaptosomal Rigidity in Senescence-Accelerated Mice *Gerard Piñol-Ripoll, Dario Acuna-Castroviejo, Ana Coto-Montes, Joaquin Garcia*